The prevalence of latent/chronic infection in liver transplant candidates in Taleghani Hospital of Tehran, Iran, from 2020 until 2021
Gastroenterology and Hepatology from Bed to Bench,
Vol. 16 No. 1 (2023),
2 January 2023
https://doi.org/10.22037/ghfbb.v16i1.2664
Abstract
Aim: The present study aimed to study the prevalence of various latent infections in pre-transplanted patients.
Background: Due to chronic immunosuppressive therapy, patients receiving organ transplants are at risk for reactivation of various infections. Due to the complications in the course of diagnosing and treating the post-transplant infection, screening transplant recipients and donors is vital.
Methods: This retrospective cohort study was performed between March 2020 and 2021. A total of 193 patients receiving a liver transplant in Taleghani Hospital, Tehran, Iran were enrolled.
Results: One-hundred and three (53.4%) patients were men, with an average age of 48.4 ± 13.3 years. Among viruses, 177 (91.7%) patients had a positive IgG titer for CMV. Anti-EBV IgG was positive in 169 (87.6%) patients. One-hundred and seventy-five (90.7%) patients had a positive IgG titer for the VZV. One-hundred and sixty-six (86.0%) cases had positive IgG anti-HSV antibodies. According to our findings, none of the patients were infected with HIV, but 9 (4.7%) cases and 141 (73.1%) had positive anti-HCV and anti-HAV IgG antibodies, respectively. HBV surface (HBs) antigen was also reported positive in 17 (8.8%) patients, while the HBs antibody was positive in 29 (15.0%) patients.
Conclusion: In our study, most of the patients had positive serology for latent viral infections such as CMV, EBV, VZV, and HSV, but the prevalence of latent tuberculosis and viral hepatitis was low among transplant candidates.
- Latent infections, liver transplant, CMV IgG, Infection reactivation, Transplant candidat
How to Cite
References
Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the 21st century. Ann Transl Med 2018;6:409.
Claeys E, Vermeire K. Immunosuppressive drugs in organ transplantation to prevent allograft rejection: Mode of action and side effects. J Immunol 2019;3:14-21.
Raza S, Rajak S, Upadhyay A, Tewari A, Sinha RA. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed) 2021;26:206-237.
Graham CN, Watson C, Barlev A, Stevenson M, Dharnidharka VR. Mean lifetime survival estimates following solid organ transplantation in the US and UK. J Med Econ 2022;25:230-237.
Rana A, Gruessner A, Agopian VG, Khalpey Z, Riaz IB, Kaplan B, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg 2015;150:252-259.
Singh N. The current management of infectious diseases in the liver transplant recipient. Clin Liver Dis 2000;4:657-673.
Ho M, editor Advances in understanding cytomegalovirus infection after transplantation. Transplant Proc 1994;26:7-11.
Miller G, Dummer J. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant 2007;7:741-747.
Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965;58:9-20.
Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997;10:86-124.
Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-2614.
GREEN M. Guidelines for the prevention and management of infectious complications of solid organ transplantation. Am J Transplant 2004;10:5-166.
Avery RK. Recipient screening prior to solid-organ transplantation. Clin Infect Dis 2002;35:1513-1519.
Avery RK. Prophylactic strategies before solid-organ transplantation. Curr Opin Infect Dis 2004;17:353-356.
Goletti D, Delogu G, Matteelli A, Migliori GB. The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. Int J Infect Dis 2022;124:12-19.
Nayak S, Acharjya B. VDRL test and its interpretation. Indian J Dermatol 2012;57:3-8.
Grauhan O, Lohmann R, Lemmens P, Schattenfroh N, Jonas S, Keck H, et al. Mycobacterial infection after liver transplantation. Langenbecks Arch Chir 1995;380:171-175.
Qunibi WY, al-Sibai MB, Taher S, Harder EJ, de Vol E, al-Furayh O, et al. Mycobacterial infection after renal transplantation--report of 14 cases and review of the literature. Q J Med 1990;77:1039-1060.
Morduchowicz G, Pitlik SD, Shapira Z, Shmueli D, Yussim A, Djalovski S, et al. Infections in renal transplant recipients in Israel. Isr J Med Sci 1985;21:791-797.
Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005;40:581-587.
Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 1998;27:1266-1277.
Subramanian AK, Theodoropoulos NM, Infectious Diseases Community of Practice of the American Society of T. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant 2019;33:13513.
Subramanian AK, Theodoropoulos NM; Infectious Diseases Community of Practice of the American Society of Transplantation. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant. 2019 Sep;33(9):e13513. doi: 10.1111/ctr.13513. Epub 2019 Mar 22. PMID: 30817030.
Chen CY, Liu CJ, Feng JY, Loong CC, Liu C, Hsia CY, et al. Incidence and risk factors for tuberculosis after liver transplantation in an endemic area: a nationwide population-based matched cohort study. Am J Transplant 2015;15:2180-2187.
Lauar ID, Faria LC, Romanelli RMC, Clemente WT. Latent tuberculosis: Risk factors, screening and treatment in liver transplantation recipients from an endemic area. World J Transplant 2021;11:512-522.
Novick RJ, Moreno-Cabral CE, Stinson EB, Oyer PE, Starnes VA, Hunt SA, et al. Nontuberculous mycobacterial infections in heart transplant recipients: a seventeen-year experience. J Heart Transplant 1990;9:357-363.
Moddry DL, Stinson EB, Dyer PE, Jamieson SW, Baldwin JC, Shumway NE. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation. 1985;39:313-314.
Rajagopala S, Olithselvan A, Varghese J, Shanmugam N, Rela M. Latent Mycobacterium tuberculosis Infection in Liver Transplant Recipients-Controversies in Current Diagnosis and Management. J Clin Exp Hepatol 2011;1:34-37.
Lopez de Castilla D, Schluger NW. Tuberculosis following solid organ transplantation. Transpl Infect Dis 2010;12:106-112.
Ozgen Alpaydin A, Ozbilgin M, Abdulleyeva M, Mersin SS, Egeli T, Unek T, et al. Determinants and characteristics of tuberculosis in liver transplant recipients. Turk J Med Sci 2018;48:1162-1166.
Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009;48:1657-1665.
Imai S, Ito Y, Hirai T, Imai H, Ito I, Maekawa K, et al. Clinical features and risk factors of tuberculosis in living-donor liver transplant recipients. Transpl Infect Dis 2012;14:9-16.
Malinis M, Boucher HW, Practice ASTIDCo. Screening of donor and candidate prior to solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33:13548.
Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005;62:7-13.
Dummer JS, Hardy A, Poorsattar A, Ho M. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation 1983;36:259-267.
Cheeseman SH, Rubin RH, Stewart JA, Tolkoff-Rubin NE, Cosimi AB, Cantell K, et al. Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med 1979;300:1345-1349.
Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol 2015;235:288-297.
Zuckerman RA, Limaye AP. Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients. Am J Transplant 2013;13:55-66.
Singh N, Dummer JS, Kusne S, Breinig MK, Armstrong JA, Makowka L, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988;158:124-131.
Gray J, Wreghitt TG, Pavel P, Smyth RL, Parameshwar J, Stewart S, et al. Epstein-Barr virus infection in heart and heart-lung transplant recipients: incidence and clinical impact. J Heart Lung Transplant 1995;14:640-646.
Garnier JL, Berger F, Betuel H, Vuillaume M, Chapuis-Cellier C, Blanc N, et al. Epstein-Barr virus associated lymphoproliferative diseases (B cell lymphoma) after transplantation. Nephrol Dial Transplant 1989;4:818-823.
Preiksaitis JK, Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 2001;33:38-46.
Silva JT, Fernández-Ruiz M, Aguado JM. Prevention and therapy of viral infections in patients with solid organ transplantation. Enferm Infecc Microbiol Clin 2021;39:87-97.
Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. Transpl Infect Dis 2008;10:260-268.
Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine 1988;67:132-143.
Janier M, Hegyi V, Dupin N, Unemo M, Tiplica GS, Potocnik M, et al. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol 2014;28:1581-1593.
Stoltey JE, Cohen SE. Syphilis transmission: a review of the current evidence. Sex Health 2015;12:103-109.
Ison MG, Nalesnik MA. An update on donor-derived disease transmission in organ transplantation. Am J Transplant 2011;11:1123-1130.
Samuel D, Bismuth A, Serres C, Arulnaden JL, Reynes M, Benhamou JP, et al. HBV infection after liver transplantation in HBsAg positive patients: experience with long-term immunoprophylaxis. Transplant Proc 1991;23:1492-1494.
Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997;10:86-124.
Davis CL, Gretch DR, Carithers Jr RL. Hepatitis B and transplantation. Infect Dis Clin N Am 1995;9:925-941.
Pereira BJ, Natov SN, Bouthot BA, Murthy B, Ruthazer R, Schmid CH, et al. Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998;53:1374-1381.
Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991;325:454-460.
Bogers A, van't Wout J, Cats VM, Quaegebeur J, Huysmans H. Mediastinal rupture of a thoracoabdominal mycotic aneurysm caused by Salmonella typhimurium in an immunocompromised patient. Eur J Cardiothorac Surg 1987;1:116-118.
Caccamo L, Colledan M, Gridelli B, Rossi G, Doglia M, Gatti S, et al. Hepatitis C virus infection in liver allograft recipients. Arch Virol Suppl 1993;8:291-304.
Roth D, Zucker K, Cirocco R, DeMattos A, Burke GW, Nery J, et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int 1994;45:238-244.
- Abstract Viewed: 141 times
- PDF Downloaded: 120 times